9.4
[1]. Kobayashi H, et al. Effects of polymorphisms in CYPD6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib. Med Oncol. 016 Jun;33(6):5.
[]. McKillop D, et al. Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition. Xenobiotica. 006 Jan;36(1):9-39.
H30-H315-H319-H335
P61-P64-P0-P1-P80-P30+P35-P304+P340-P330-P36+P364-P405-P501
GHS0